Open an account

Veracyte

VCYT · NASDAQ

$44.79+$0.99 (+2.26%)TodayMarket closed ·
Prev close $43.80

About VCYT

Veracyte, Inc. engages in the research, development and commercialization of diagnostic products. The company is headquartered in South San Francisco, California and currently employs 755 full-time employees. The company went IPO on 2013-10-30. The firm enables clinicians with insights they need to guide and help patients to diagnose and treat cancer. The Veracyte Diagnostics Platform delivers cancer tests that are fueled by broad genomic and clinical data, deep bioinformatic and AI capabilities, and an evidence-generation engine, which drives durable reimbursement and guideline inclusion for its tests, along with new insights to support continued innovation and pipeline development. The firm offers tests for prostate cancer (Decipher Prostate), thyroid cancer (Afirma), breast cancer (Prosigna) and bladder cancer (Decipher Bladder). The company has developed the noninvasive Percepta Nasal Swab test to help physicians accurately and quickly determine lung cancer risk. All of its tests are serviced through its own Clinical Laboratory Improvement Amendments (CLIA) certified laboratories in South San Francisco, California, San Diego, California and Austin, Texas.

Employees
755
Headquarters
South San Francisco, California
Listed
Oct 30, 2013
Sector
Health Care
Industry
Biotechnology
Website
veracyte.com

VCYT key statistics

Market cap
3.47B
Price-earnings ratio
31.29
Dividend yield
—
Average volume
1.38M
Volume
1.14M
Open price
$43.91
High today
$45.17
Low today
$43.47
52 Week high
$60.91
52 Week low
$29.46

Veracyte (VCYT) at a glance

As of Oct 20, 2026, Veracyte (VCYT) shares are priced at $44.79, giving the company a market cap of 3.47B and a price-to-earnings ratio of 31.29.

Today the stock has traded between $43.47 and $45.17. The current price is 3.0% above the day's low and 0.8% below its high.

Volume so far is 1.14M shares, in line with the average of 1.38M shares a day.

Over the past year Veracyte has ranged from $29.46 to $60.91, and now sits 49% of the way up that range.

Veracyte met or beat analyst EPS estimates in 6 of the last 8 quarters. In Q2 FY26 it reported $0.31 per share against an estimate of $0.2652.

The average analyst price target is $59.59, 33.0% above the current price, from 10 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

80%of 10 analyst ratings say Buy
  • Buy80.0%
  • Hold10.0%
  • Sell10.0%
Price target · 14 analystsAvg $59.59
Low
$44.44
Now
$44.79
High
$73.50

VCYT earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 6 of the last 8 quarters, by 168.7% on average.

  1. Q3 FY24: reported $0.19 per share against an estimate of $0.028
  2. Q4 FY24: reported $0.06 per share against an estimate of $0.1166
  3. Q1 FY25: reported $0.09 per share against an estimate of $0.0523
  4. Q2 FY25: reported -$0.01 per share against an estimate of $0.0969
  5. Q3 FY25: reported $0.24 per share against an estimate of $0.1341
  6. Q4 FY25: reported $0.51 per share against an estimate of $0.2193
  7. Q1 FY26: reported $0.35 per share against an estimate of $0.1501
  8. Q2 FY26: reported $0.31 per share against an estimate of $0.2652

VCYT news

  • Chandrima Sanyal

    Cathie Wood's $22M Biotech Shuffle, Dumps One Stock for 21st Straight Session While Other Bets Pile Up

  • Chandrima Sanyal

    Cathie Wood Loads Up On Biotech: 5 ETFs Holding Her Latest Bets

  • Press releaseBusiness Wire

    Veracyte to Release Second Quarter 2026 Financial Results on July 30, 2026

  • Shivdeep Dhaliwal

    Cathie Wood Sells Robinhood Stock, Doubles Down On This George Soros-Backed AI Stock

  • Press releaseBusiness Wire

    Veracyte Announces Commercial Launch of the Prosigna Breast Test in the U.S.

  • Press releaseBusiness Wire

    ENZAMET Trial Shows Veracyte's Decipher Prostate Test Identifies Which Patients Benefit from Adding Chemotherapy in Metastatic Prostate Cancer

  • Press releaseBusiness Wire

    Landmark OPTIMA Trial Delivers Practice-Changing Evidence that Veracyte's Prosigna Test Identifies Patients with High-Risk Breast Cancer Who Can Safely Avoid Chemotherapy

  • Press releaseBusiness Wire

    Veracyte to Host Investor Call on June 1, 2026 to Discuss ASCO Findings

Similar companies

Companies in the same industry as Veracyte

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.